ArticleScientific reports2016
Curcumin protects ANIT-induced cholestasis through signaling pathway of FXR-regulated bile acid and inflammation.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 58 citations in OpenAlex.
- A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial.European journal of clinical nutrition · 2019Trial
- Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.Scandinavian journal of gastroenterology · 2019Trial
- Selenium pretreatment alleviates ANIT-induced cholestasis by preserving BSEP expression and hepatic redox homeostasis.Molecular biology reports · 2026Article
- Interactions of bile acids and gut microbiota modulate neurological health: a comprehensive review on mechanisms and therapeutic potential of dietary phytochemicals.Frontiers in microbiology · 2026Review
- Curcumin-based compounds in non-malignant biliary injury and cholangiocarcinoma: mechanistic insights and translational barriers.Frontiers in pharmacology · 2026Review
- Article
- Curcumin Mitigates Gut Dysbiosis and Enhances Gut Barrier Function to Alleviate Metabolic Dysfunction in Obese, Aged Mice.Biology · 2024Article
- Functional metabolomics characterizes the contribution of farnesoid X receptor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.Archives of toxicology · 2024Article
- Farnesoid X receptor: From Structure to Function and Its Pharmacology in Liver Fibrosis.Aging and disease · 2024Review
- How traditional Chinese medicine can prevent recurrence of common bile duct stones after endoscopic retrograde cholangiopancreatography?Frontiers in pharmacology · 2024Review
- Natural compounds targeting nuclear receptors for effective cancer therapy.Cancer metastasis reviews · 2023Review
- Bile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols.Pharmacology & therapeutics · 2023Review
- Farnesoid X receptor regulators from natural products and their biological function.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023Article
- Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products.Frontiers in immunology · 2023Review
- Farnesoid X receptor is inhibited after ileum transposition in diabetic rats: its hypoglycemic effect.International journal of medical sciences · 2023Article
- Network Proximity-Based Drug Repurposing Strategy for Early and Late Stages of Primary Biliary Cholangitis.Biomedicines · 2022Article
- The serum acylcarnitines profile in epileptic children treated with valproic acid and the protective roles of peroxisome proliferator-activated receptorFrontiers in pharmacology · 2022Article
- Curcumin modulates gut microbiota and improves renal function in rats with uric acid nephropathy.Renal failure · 2021Article
- Improving glucose and lipids metabolism: drug development based on bile acid related targets.Cell stress · 2021Review
- Piceatannol attenuates fat accumulation and oxidative stress in steatosis-induced HepG2 cells.Current research in food science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholestasis is a clinically significant symptom and widely associated with liver diseases, however, there are very few effective therapies for cholestasis. Danning tablet (DNT, a Chinese patent medicine preparation) has been clinically used to treat human liver and gallbladder diseases for more than 20 years in China. However, which ingredients of DNT contributed to this beneficial effect and their mechanistic underpinnings have been largely unknown. In the present study, we discovered that DNT not only demonstrated greater benefits for cholecystitis patients after cholecystectomy surgery in clinic but also showed protective effect against alpha-naphthylisothiocyanate (ANIT)-induced cholestasis model in rodent. Curcumin, one major compound derived from DNT, exerted the protective effect against cholestasis through farnesoid X receptor (FXR), which has been focused as potential therapeutic targets for treating cholestasis. The underlying mechanism of curcumin against cholestasis was restoring bile acid homeostasis and antagonizing inflammatory responses in a FXR-dependent manner and in turn contributed to overall cholestasis attenuation. Collectively, curcumin can be served as a potential treatment option for liver injury with cholestasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.